This dual approach can be particularly beneficial for patients with type 2 diabetes and obesity, as weight reduction itself improves insulin sensitivity and metabolic parameters
8 This study, which took place over a five-year period, surely contributed to the FDAs approval of semaglutide in early 2024 for use in this population, and demonstrated that, in addition to managing diabetes and obesity, GLP1 receptor agonists offer value in reducing cardiovascular event risk
The Muscle Loss Myth: Its Not the Drug, Its the Protocol Lets clarify something critical: muscle loss during GLP-1 therapy is not an inevitable side effect
This option provides built-in accountability and regular check-ins with our team
The peptide protocol described above is prescribed by me, sourced through a US cGMP-certified compounding pharmacy, dosed for the patient and the procedure, and integrated into a recovery plan I have built operating on local, national, and international patients for the last fifteen years
#EllieMD #HealthcareInnovation #Longevity #Peptides #Wellness